Drugs
Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels
Pharmacogenomic information is contained in about ten percent of labels for drugs approved by the FDA. A significant increase of labels containing such information has been observed over the last decade. In order to provide a reference for genomic biomarkers in labels of FDA-approved drug products, we created the table shown below. Genomic biomarkers can play an important role in identifying responders and non-responders, avoiding toxicity and adjusting the dosage of drugs to optimize their efficacy and safety. In the context of drug labels, these genomic biomarkers can be classified on the basis of their specific use, for example:
- Clinical response and differentiation,
- Risk identification,
- Dose selection guidance,
- Susceptibility, resistance and differential disease diagnosis,
- Polymorphic drug targets.
The table portrays a view on valid genomic biomarkers in the context of FDA-approved drug labels. It provides a comprehensive list of these markers and links to pharmacogenomic data, taking into account multiple regulatory contexts in which these biomarkers were approved. Most drug labels in this table provide pharmacogenomic information with no immediate recommendation for a specific action (i.e. genetic testing); however a few labels recommend or require genetic testing thereby specifying the use of these markers for reaching a therapeutic decision.
The table includes:
- Context-specific biomarker (column 1)
- Reference drug label information about the biomarker context within which the drug was approved (column 2 subsection 1)
- Prototypic drug associated with the label information defining the biomarker context (column 2 subsection 2)
- Other drugs in a similar context (column 3)
- Pertinent references (column 4).
Drugs sharing the context of a specific biomarker in their labels have had their pharmacogenomic information extracted into this table. This information can be accessed by placing the mouse over the symbol under the right side of the drug name. All approved drugs in this table are linked to labels at Drugs@FDA which can be accessed by clicking over symbols under the left side of the drug name. The table will be updated on a quarterly basis.
The information provided in “label context” is taken from different sections of the actual drug labels.
The term “valid” biomarker has been defined in the “Guidance for Industry: Pharmacogenomic Data Submissions”. Therein, a valid biomarker is described as a “biomarker that is measured in an analytical test system with well established performance characteristics and for which there is an established scientific framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic, or clinical significance of the test results.” The classification of biomarkers is context specific.
A critical aspect of many of these drugs is the role they play in drug-drug interactions. This list does not address drug-drug interactions. More information on drug-drug interactions, please see Drug Development and Drug Interactions.
| Biomarker | Label Context | Examples of other Drugs Associated with this Biomarker | References (PubMed ID) |
|
|---|---|---|---|---|
| Representative Label |
Drug | |||
| C-KIT expression | Gastrointestinal stromal tumor c-Kit expression “In vitro, imatinib inhibits proliferation and induces apoptosis in gastro-intestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.” “Gleevec is also indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).” | Imatinib mesylate | 12851888 16226710 16294026 |
|
| CCR5 -Chemokine C-C motif receptor | CCR5 is a receptor site on the human T-cell that HIV uses to bind to the cell allowing it to enter and begin replication. “SELZENTRY, in combination with other antiretroviral agents, is indicated for treatment experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.” “SELZENTRY blocks a specific receptor called CCR5 that CCR5-tropic HIV-1 uses to enter CD4 or T-cells in your blood. Your doctor will do a blood test to see if you have been infected with CCR5-tropic HIV-1 before prescribing SELZENTRY for you.” “Pharmacogenomics The impact of CCR5 promoter and coding sequence polymorphisms on the efficacy of maraviroc is being evaluated.” |
Maraviroc |
17933726 17933725 17933724 17933723 17933722 |
|
| CYP2C19 Variants | CYP2C19 poor metabolizer status is associated with diminished response to Clopidogrel. The optimal dose regimen for poor metabolizers has yet to be determined. (Dosage and Administration-Pharmacogenetics) Based on Literature data, patients with genetically reduced CYP2C19 function have lower systemic exposure to the active metabolite of clopidogrel and diminished antiplatelet responses and generally exhibit higher cardiovascular event rates following myocardial infraction than do patients with normal CYP2C19 function. (Precautions-Pharmacogenetics) CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidrogrel intermediate metabolite. Clopidrogrel active metabolite pharmacokinetic and antiplatelet effects as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotypes. The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethinicity. (Clinical Pharmacology-Pharmacogenetics) | Clopidogrel | 19636246 19576320 19537521 19463375 19429918 19414633 19106083 19268736 19193675 19108880 19487603 19106084 19414633 18482659 |
|
| CYP2C19 Variants with alternate context | CYP2C19 Variants (Poor Metabolizers-PM and Extensive Metabolizers-EM) with genetic defect leads to change in drug exposure. “In vivo studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolizers. For Caucasians and Blacks, the prevalence of poor metabolizers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolizers have, on average, 4-fold higher voriconazole exposure (AUCτ) than their homozygous extensive metabolizer counterparts. Subjects who are heterozygous extensive metabolizers have, on average, 2-fold higher voriconazole exposure than their homozygous extensive metabolizer counterparts.” | Voriconazole | Omeprazole[m1] Pantoprazole [m2] Esomeprazole[m3] diazepam[m4] Nelfinavir[m5] Rabeprazole[m6] |
12867215 11866669 |
| CYP2C19 Variants with alternate context (no effect of Variants) | 8.9 Metabolic Status In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving prasugrel, there was no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel’s active metabolite or its inhibition of platelet aggregation. (8. Use in Special Populations) There is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of 352 prasugrel’s active metabolite or its inhibition of platelet aggregation. (12 Clinical Pharmacology- 12.5 Pharmacogenomics) Whereas the pharmacokinetics of prasugrel’s active metabolite are not known to be affected by genetic variations in CYP2B6, CYP2C9, CYP2C19, or CYP3A5, the pharmacokinetics of clopidogrel’s active metabolite are affected by CYP2C19 genotype, and approximately 30% of Caucasians are reduced-metabolizers (14 Clinical Studies). | Prasugrel |
1953752
|
|
| CYP2C9 Variants | CYP2C9 Variants PM and EM genotypes and drug exposure; “Patients who are known or suspected to be P450 2C9 poor metabolizers based on a previous history should be administered celecoxib with caution as they may have abnormally high plasma levels due to reduced metabolic clearance.” | Celecoxib | 16118328 15637526 15714076 15037866 14558433 |
|
| CYP2C9 Variants with alternate context | CYP2C9 Variant genotypes and drug dose “The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.” | Warfarin | 18034618; 17989110; 17955230 |
|
| CYP2D6 Variants | CYP2D6 Variants “Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs).” | Atomoxetine | Venlafaxine;[m8] Risperidone;[m9] Tiotropium bromide inhalation;[m10] Tamoxifen;[m11] Timolol Maleate;[m12] |
|
| CYP2D6 with alternate context | CYP2D6 PM and EM Variants and drug exposure and risk- “population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6. Fluoxetine, like other agents that are metabolized by P450IID6, inhibits the activity of this isoenzyme, and thus may make normal metabolizers resemble "poor metabolizers." Therapy with medications that are predominantly metabolized by the P450IID6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks.” | Fluoxetine HCL |
Fluoxetine HCL and Olanzapine;[m13] |
16472103 16384813; 15063083; 16271013 16236141 15828850 15492763 15037866 14639062 10431214 1302039 |
| CYP2D6 (UM) with alternate context | 5.9 Ultra-rapid Metabolizers of Codeine Some individuals may be ultra-rapid metabolizers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5% to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. (Precautions 5) When physicians prescribe codeine-containing drugs, they should choose the lowest effective dose for the shortest period of time and inform their patients about these risks and the signs of morphine overdose. [see Use in Specific Populations (8)] There is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on the pharmacokinetics of prasugrel’s active metabolite or its inhibition of platelet aggregation. (12 Clinical Pharmacology 12.5 Pharmacogenomics) Whereas the pharmacokinetics of prasugrel’s active metabolite are not known to be affected by genetic variations in CYP2B6, CYP2C9, CYP2C19, or CYP3A5, the pharmacokinetics of clopidogrel’s active metabolite are affected by CYP2C19 genotype, and approximately 30% of Caucasians are reduced-metabolizers. (14 Clinical Studies) |
Codeine sulfate |
Fiorinal with Codeine (butalbital, aspirin, caffeine, and codeine phosphate) Fioricet with Codeine (butalbital, acetaminophen, caffeine, and codeine phosphate) |
|
| Deletion of Chromosome 5q(del(5q)) | Cytogenetic abnormality in management of Low- or Intermediate-1 risk myelodysplastic syndromes -“Lenalidomide is indicated for the treatment of patients with transfusion dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.” | Lenalidomide | 18265982 17893227 17634837 17379099 16397017 |
|
| DPD Deficiency | Deficiency of Dihydropyrimidine Dehydrogenase: “Rarely, unexpected, severe toxicity (eg, stomatitis, diarrhea, neutropenia and neurotoxicity) associated with 5-fluorouracil has been attributed to a deficiency of dihydropyrimidine dehydrogenase (DPD) activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-fluorouracil therefore cannot be excluded. | Capecitabine | Fluorouracil Cream; [m27] Fluorouracil Topical Solution & Cream[m28] |
16428499 16163233 15377401 15093568 15083629 |
| EGFR expression | Epidermal Growth Factor Receptor presence or absence- “EGFR expression was determined using the EGFR pharmDxTM kit. In contrast to the 1% cut-off specified in the pharmDx kit instructions, a positive EGFR expression status was defined as having at least 10% of cells staining for EGFR. The pharmDx kit has not been validated for use in pancreatic cancer. An apparently larger effect, however, was observed in two subsets: patients with EGFR positive tumors (HR = 0.68) and patients who never smoked (HR = 0.42). Analysis of the impact of EGFR expression status on the treatment effect on clinical outcome is limited because EGFR status is known for 326 NSCLC study patients (45%).” | Erlotinib | 16354309 16011858 |
|
| EGFR expression with alternate Context | Epidermal Growth Factor Receptor presence or absence- “Pretreatment assessment for evidence of EGFR expression is not required for patients with squamous cell carcinoma of head and neck (SCCHN).” | Cetuximab Head and Neck Cancer |
Gefitinib[m29] | 16354869 16336755 16336752 16117976 16061873 15962524 15863375 15946581 15677699 15217966 |
| EGFR expression with alternate Context | Epidermal Growth Factor Receptor presence or absence- “Patients enrolled in the clinical studies were required to have immuno-histochemical evidence of positive EGFR expression using the DakoCytomation EGFR pharmDx™ test kit.” | Cetuximab Colorectal Cancer |
Panitumab [m30] Gefitinib [m29] |
16354869 16336755 16336752 16117976 16061873 15962524 15863375 15946581 15677699 15217966 |
| Familial Hypercholestremia (deficiency, and/or mutation, of receptors for low density lipoprotein -LDL) | Dosage adjustment for Homozygous and heterozygous Familial Hypercholestremia “Doses should be individualized according to the recommended goal of therapy. Homozygous Familial Hypercholestremia (10-80mg/day)and heterozygous (10-20mg/day) Familial Hypercholestremia dose adjustment needed in pediatric patients.” | Atorvastatin |
17056835 14512370 12145769 |
|
| G6PD Deficiency | G6PD deficiency and risk “Rasburicase administered to patients with glucose- phosphate dehydrogenase (G6PD) deficiency can cause severe hemolysis. ELITK administration should be immediately and permanently discontinued in any patient developing hemolysis. It is recommended that patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) be screened prior to starting ELITEK therapy (see CONTRANDICATIONS and WARNINGS, Hemolysis).” | Rasburicase | Dapsone[m31] | 16204390 11842483 |
| G6PD Deficiency with alternate Context | G6PD deficiency and tolerance “Hemolytic reactions (moderate to severe) may occur in glucose-6-phosphate dehydrogenase (G-6-PD) deficient. If primaquine phosphate is prescribed for an individual with erythrocytic glucose-6-phosphatedehydrogenase (G-6-PD) deficiency or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency, the person should be observed closely for tolerance.” | Primaquine | Chloroquine[m32] | 15330059 15117307 12643993 9685977 |
| Her2/neu Over-expression | Overexpresion of Her2/neu necessary for selection of patients appropriate for drug therapy “Detection of HER2 protein overexpression is necessary for selection of patients appropriate for HERCEPTIN therapy (see INDICATIONS).” “HERCEPTIN should be used in patients whose tumors have been evaluated with an assay validated to predict HER2 protein overexpression (see PRECAUTIONS: HER2 Testing and CLINICAL STUDIES: HER2 Detection).” |
Trastuzumab | Lapatinib [m33] | 18188694 17921724 17909820 16445668 16277882 16137435 15725114 15143970 14990641 |
| HLA-B*1502 allele presence | “SERIOUS DERMATOLOGIC REACTIONS AND HLA-B*1502 ALLELE.” “Prior to initiating Tegretol therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry. Tegretol should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN (see WARNINGS and PRECAUTIONS/Laboratory Tests).” ”For genetically at-risk patients (See WARNINGS), high-resolution ‘HLA-B*1502 typing’ is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.” | Carbamazepine |
18192896 18085998 17697703 17620823 17509004 16981842 16538176 16415921 15057820 |
|
| HLA-B*5701 allele presence |
WARNING: HYPERSENSITIVITY REACTIONS/LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you: have been tested and know whether or not you have a particular gene variation called HLA-B*5701. |
Abacavir | 18256392 18444831 18614879 18549801 18505179 18370849 18332899 18303141 18192781 18184080 18025891 18018760 17885623 17631508 17620824 17534855 17356469 |
|
| KRAS mutation (Lack of Efficacy of Anti-EGFR Monoclonal Antibodies in Patients with mCRC Containing KRAS Mutations) | Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer with these mutations. (Indication and Usage) Lack of Efficacy of Anti-EGFR Monoclonal Antibodies in Patients With mCRC Containing KRAS Mutations Retrospective analyses as presented in Table 2 across seven randomized clinical trials suggest that anti-EGFR-directed monoclonal antibodies are not effective for the treatment of patients with mCRC containing KRAS mutations. (Clinical Studies) Signal transduction through the EGFR results in activation of the wild-type KRAS protein. However, in cells with activating KRAS somatic mutations, the mutant KRAS protein is continuously active and appears independent of EGFR regulation. (Clinical Pharmacology-Mechanism of Action) |
Panitumumab | Cetuximab | 19636327 19632927 19616446 19546597 19546608 19471640 19468688 19411318 19390304 19384694 19378369 19368524 19352138 19337429 19309232 19293803 19223544 19189371 19188670 19124802 19117687 19086328 19056857 19004722 19001320 18998757 18810446 18419758 18316791 18230579 |
| NAT Variants | N-acetyltransferase slow and fast acetylators and toxicity- “slow acetylation may lead to higher blood levels of the drug, and thus, an increase in toxic reactions.” | Rifampin, isoniazid, and pyrazinamide | Isosorbide dinitrate and Hydralazine hydrochloride[m34] | 12669770 12715953 2224079 12271964 11259359 11677864 15951616 |
| Philadelphia Chromosome-positive responders | Philadelphia (Ph1) chromosome presence (effective) -“Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Also, the so-called “juvenile” type of chronic myelogenous leukemia, typically occurring in young children and associated with the absence of a Philadelphia chromosome, responds poorly to busulfan. The drug is of no benefit in patients whose chronic myelogenous leukemia has entered a “blastic” phase.” | Busulfan | 11919388 | |
| Philadelphia Chromosome- positive responders with alternate context | Philadelphia (Ph1) chromosome presence (effective) “Dasatinib is indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.” | Dasatinib | Nilotinib [m35] | 17461740 14633780 |
| PML/RAR alpha gene expression (Retinoic acid receptor responder and non-responders) | PML/ RAR (alpha) fusion gene presence “Initiation of therapy with VESANOID may be based on the morphological diagnosis of acute promyelocytic leukemia (APL). Confirmation of the diagnosis of APL should be sought by detection of the t (15; 17) genetic marker by cytogenetic studies. If these are negative, PML/ RAR (alpha) fusion should be sought using molecular diagnostic techniques. The response rate of other AML subtypes to VESANOID has not been demonstrated; therefore, patients who lack the genetic marker should be considered for alternative treatment.” | Arsenic Oxide [m36] | 15735696 11114710 |
|
| Protein C deficiencies (hereditary or acquired) | Hereditary or acquired deficiencies of protein C or its cofactor, protein S, has been associated with tissue necrosis following warfarin administration. “Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies. Inherited resistance to activated protein C has been described in many patients with venous thrombosis-embolic disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent thrombosis and for adverse reactions, is difficult to evaluate since it does not appear to be the same for everyone. Decisions about testing and therapy must be made on an individual basis.” | Warfarin | 16444443 10718793 8913415 |
|
| TPMT Variants | “Thiopurine methyltransferase deficiency or lower activity due to mutation at increased risk of myelotoxicity. TPMT testing is recommended and consideration be given to either genotype or phenotype patients for TPMT.” | Azathioprine | Thioguanine[m37] Mercaptopurine [m38] |
16409140 16267626 15792824 15571264 15570193 15316356 15226673 14985890 12465143 10628931 7857117 |
| UGT1A1 Variants |
UGT1A1 mutation in patients, exposure to drug and hence their susceptibility to toxicity. “Individuals who are homozygous for the UGT1A*28 allele are at increased risk for neutropenia following initiation of camptosar treatment. A reduced initial dose should be considered for patients known to be homozygous for the UGT1A*28 allele. Heterozygous patients may be at increased risk of neutropenia; however clinical results have been variable and such patients have been shown to tolerate normal starting doses.” | Irinotecan | 15297419 15280927 15007088 15084617 |
|
| UGT1A1 variants with alternate context | Pharmacogenomics (safety) “Tasigna can increase bilirubin levels. A pharmacogenetic analysis of 97 patients evaluated the polymorphisms of UGT1A1 and its potential association with hyperbilirubinemia during Tasigna treatment. In this study, the (TA)7/(TA)7 genotype was associated with a statistically significant increase in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. However, the largest increases in bilirubin were observed in the (TA)7/(TA)7 genotype (UGT1A1*28) patients [See Warnings and Precautions (5.5)].” |
Nilotinib | 17611564 | |
| Urea Cycle Disorder (UCD) Deficiency | Urea cycle disorders – “Prior to the initiation of valproate therapy, evaluation for UCD should be considered.” | Valproic acid | Sodium Phenylacetate and Sodium Benzoate; sodium phenyl butyrate | 16100994 16136341 15465784 10098145 |
| Vitamin K epoxide reductase (VKORC1) Variants | Vitamin K epoxide reductase (VKOR) Variant- ““Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G).A allele) have been associated with lower dose requirements for warfarin. About 55% of the variability in warfarin dose could be explained by the combination of VKORC 1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients. Similar observations have been reported in Asian patients.” | Warfarin | 18034619; 18030307; 17955831; 17912794; 17906972 |
|
Cited by:
Bhathena A, Spear BB.
Pharmacogenetics: improving drug and dose selection. Curr Opin Pharmacol 2008 Oct; 8(5):639-46. Epub 2008 Sep 26 (PMID: 18762278)Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, Deluca TM, Verbrugge RR, Burckart GJ, Lesko LJ.
Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Pharmacotherapy. 2008 Aug;28(8):992-8 (PMID: 18657016)Nakamura Y.
Pharmacogenomics and Drug Toxicity.
N Engl J Med. 2008 Jul 23 (PMID: 18650508)Shashi Amur, Felix Frueh, Lawrence Lesko and Shiew-Mei Huang
Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
Biomarkers in Medicine, June 2008; Vol. 2, No. 3, Pages 305-311 (doi:10.2217/17520363.2.3.305), http://www.futuremedicine.com/doi/abs/10.2217/17520363.2.3.305Marrer E, Dieterle F.
Promises of biomarkers in drug development--a reality check.
Chem Biol Drug Des. 2007 Jun; 69(6):381-94 (PMID: 17581232)Goodsaid F, Frueh F.
Biomarker qualification pilot process at the US Food and Drug Administration.
AAPS J. 2007 Mar 23;9(1):E105-8 (PMID: 17408233)